This short review aims to cover the more recent and promising developments of carbon-11 ( 11 C) labeling radiochemistry and its utility in the production of novel radiopharmaceuticals, with special emphasis on methods that have the greatest potential to be translated for clinical positron emission tomography (PET) imaging. A survey of the literature was undertaken to identify articles focusing on methodological development in 11 C chemistry and their use within novel radiopharmaceutical preparation. However, since 11 C-labeling chemistry is such a narrow field of research, no systematic literature search was therefore feasible. The survey was further restricted to a specific timeframe (2000–2016) and articles in English. From the literature, it is clear that the majority of 11 C-labeled radiopharmaceuticals prepared for clinical PET studies have been radiolabeled using the standard heteroatom methylation reaction. However, a number of methodologies have been developed in recent years, both from a technical and chemical point of view. Amongst these, two protocols may have the greatest potential to be widely adapted for the preparation of 11 C-radiopharmaceuticals in a clinical setting. First, a novel method for the direct formation of 11 C-labeled carbonyl groups, where organic bases are utilized as [ 11 C]carbon dioxide-fixation agents. The second method of clinical importance is a low-pressure 11 C-carbonylation technique that utilizes solvable xenon gas to effectively transfer and react [ 11 C]carbon monoxide in a sealed reaction vessel. Both methods appear to be general and provide simple paths to 11 C-labeled products. Radiochemistry is the foundation of PET imaging which relies on the administration of a radiopharmaceutical. The demand for new radiopharmaceuticals for clinical PET imaging is increasing, and 11 C-radiopharmaceuticals are especially important within clinical research and drug development. This review gives a comprehensive overview of the most noteworthy 11 C-labeling methods with clinical relevance to the field of PET radiochemistry.
No takes yet. Share an insight, caveat, or question.
Dahl et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: